SHORT COMMUNICATION

Real-life experience with inotersen in hereditary transthyretin amyloidosis with late-onset phenotype: Data from an early-access program in Italy

Marco Luigetti1,2 | Giovanni Antonini3 | Andrea Di Paolantonio2 | Luca Gentile4 | Marina Grandis5,6 | Luca Leonardi3 | Alessandro Lozza7 | Fiore Manganelli8 | Anna Mazzeo4 | Roberta Mussinelli7 | Filomena My9 | Laura Obici7 | Elena Maria Pennisi10 | Marina Romozzi1,2 | Massimo Russo4 | Mario Sabatelli11 | Alessandro Salvalaggio12 | Matteo Tagliapietra13 | Stefano Tozza8

1Fondazione Policlinico Universitario Agostino Gemelli IRCCS UOC Neurologia, Rome, Italy
2Department of Neuroscience, Catholic University of the Sacred Heart, Rome, Italy
3Department of Neurosciences, Mental Health and Sensory Organs, Faculty of Medicine and Psychology, Sant’Andrea Hospital, Sapienza University of Rome, Rome, Italy
4Unit of Neurology and Neuromuscular Diseases, Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy
5Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics and Maternal Infantile Sciences, University of Genova, Genoa, Italy
6San Martino Polyclinic Hospital, Scientific Institute for Research and Health Care, Genoa, Italy
7Amyloidosis Research and Treatment Center, San Matteo Polyclinic Foundation, Scientific Institute for Research and Health Care, Pavia, Italy
8Department of Neuroscience, Reproductive and Odontostomatological Science, University of Naples "Federico II", Naples, Italy
9UOC Neurologia Vito Fazzi Hospital, Lecce, Italy
10Neuromuscular and Rare Neurological Diseases–Neurology Unit, San Filippo Neri Hospital, Rome, Italy
11Centro Clinico NEMO Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy
12Department of Neurosciences, University of Padova, Padua, Italy
13Department of Neurosciences, Biomedicine, and Movement Sciences, University of Verona, Verona, Italy

Abstract

Background and purpose: Hereditary transthyretin (TTR) amyloidosis (ATTRv) is a dominantly inherited, adult-onset, progressive, and fatal disease caused by mutations in the transthyretin gene. Therapeutic agents approved for this disease include the TTR stabilizer tafamidis and the gene-silencing drugs patisiran and inotersen. Inotersen is an antisense oligonucleotide that suppresses the hepatic production of transthyretin. After European Medical Agency approval in 2018, an early-access program was opened in Italy, and in this article, we present the long-term outcome of a cohort of Italian ATTRv patients who received inotersen within this program.

Methods: This is a multicenter, observational, retrospective study of patients affected by ATTRv that started inotersen during the early-access program. The primary end point was safety. Secondary end points included change from baseline in familial amyloid...
INTRODUCTION

Hereditary transthyretin amyloidosis (ATTRv; v for variant), is a dominantly inherited, adult onset, progressive, and fatal disease caused by mutations in the transthyretin (TTR) gene [1,2]. TTR amyloid fibrils deposit in several tissues and organs, leading to a multisystem disorder with prevalent involvement of the peripheral nervous system and the heart [3]. The most typical presentations include a progressive sensory-motor and autonomic axonal polyneuropathy [4], and/or infiltrative cardiomyopathy. Most patients exhibit signs and symptoms of both nerve and heart involvement, but kidneys, eyes, liver, and gastrointestinal tract may also be involved [1,5].

Management therefore requires a multidisciplinary approach [1,2]. In recent years, pharmacological therapies that significantly modify the natural course of this disease have emerged, improving outcomes and prolonging survival [6]. Approved therapeutic agents include the TTR stabilizer tafamidis and the gene-silencing drugs patisiran and inotersen [7–9].

Inotersen is an antisense oligonucleotide, administered at the dosage of 284 mg subcutaneously once weekly, which suppresses the hepatic production of TTR by specifically targeting and degrading the messenger RNA of both mutant and wild-type alleles. Based on the positive results of the NEURO-TTR trial, inotersen was approved by European Medical Agency (EMA) in 2018 for the treatment of ATTRv with familial amyloid polyneuropathy (FAP) Stage 1 and 2 polyneuropathy [7].

After EMA approval, an early-access program was opened in Italy (see Supplementary Material for inclusion/exclusion criteria) to provide treatment in advance of the marketing authorization. Here, we present the long-term outcome of a cohort of patients who received inotersen within this program.

MATERIALS AND METHODS

Study design

This is a multicenter, observational, retrospective study in patients treated with inotersen from February 2019 in an early-access program according to Italian regulations.

We collected and analyzed the main clinical and laboratory parameters useful for assessing neurological and cardiac disease progression as well as safety and tolerability indicators (detailed in the Supplementary Material).

Patients and methods

Patients and outcome measure

Patients treated with inotersen within the compassionate-use program approved by the Italian Medicines Agency in February 2019 were recruited from 11 Italian centers. As routine monitoring, all patients underwent a comprehensive neurological evaluation, a cardiological examination, and laboratory tests. Serum TTR concentrations were obtained in a subgroup of patients. All parameters were evaluated at baseline and every 6 months.

Study end points

The primary end point was the safety that comprised the percentage of patients who discontinued the therapy for drug-related adverse events, including monitoring of platelet count and renal and liver function. [10] Secondary end points included change from baseline...
in FAP stage, Polyneuropathy Disability (PND) score, the Neuropathy Impairment Scale (NIS), Compound Autonomic Dysfunction Test (CADT), Norfolk Quality of Life–Diabetic Neuropathy (Norfolk QoL-DN) questionnaire, troponin, serum TTR concentration, N-terminal pro–brain natriuretic peptide (NT-proBNP), Intervertebral septum (IVS) thickness, and body mass index (BMI).

Statistical analysis

Statistical analysis was performed by SPSS version 24.0 (IBM, Armonk, NY). Data were presented as mean values with standard deviations or percentages, as appropriate. For nonnormally distributed variables, we used the Wilcoxon sign ranked test as a nonparametric significance test. Within-group changes in values over time were assessed by Friedman nonparametric test for repeated measures. A p value of <0.05 was considered statistically significant.

Patients were divided into subgroups according to genotype (V30M vs F64L vs other mutations), phenotype (neuropathic vs. mixed), previous treatment with tafamidis, the severity of disease at baseline (FAP Stage 1 vs. FAP Stage 2), and dose of inotersen (full dose vs. dose reduction). Logistic regression analysis was used to determine significant associations among covariates and dependent variables.

Ethics

The study was approved by the Ethics Committee of Fondazione Policlinico A. Gemelli IRCSS (Prot. ID 3846) as the coordinating center and then by ethics committees of other institutions.

RESULTS

Patient disposal, baseline clinical characteristics, and demographics

Twenty-three out of 31 ATTRv patients receiving inotersen in the Italian early-access program were enrolled (Figure 1). Demographic and baseline clinical characteristics are summarized in Table 1. Eleven patients (47.8%) were previously on treatment with tafamidis meglumine 20 mg/day. Serum TTR concentration at baseline was available in 12 patients (24.75 ± 5.05 mg/dl).

The mean disease duration at treatment start was 3.68 ± 2.37 years. The mean follow-up on inotersen treatment was 14.6 ± 5.9 months (range, 6–24 months).

Safety and tolerability

A significant decrease in platelet count (p = 0.001, Friedman test) was observed from baseline to month 6 (M6), but no patient permanently discontinued the treatment because of this reason and no severe thrombocytopenia (<50,000 per cubic millimeter) occurred. Pairwise comparisons highlighted that there was a significant difference between basal and M6 in mean platelet count (p = 0.017), whereas it remained stable from M6 to M24 (Supplementary Figure S1).

Five patients (21.7%) permanently discontinued the treatment due to voluntary withdrawal (two patients); renal failure after infective pyelonephritis, not drug related; drug-related hypotension; and amyloid-negative crescentic glomerulonephritis (proved by kidney biopsy), respectively. Hypotension and crescentic glomerulonephritis improved after treatment discontinuation. Mean time from the beginning of therapy to discontinuation was 305.0 ± 231.9 days (range, 92–672).

Four patients temporarily skipped the treatment for a decrease in platelet count (<75,000 per cubic millimeter) with prompt resolution of thrombocytopenia. In nine patients (39.1%), dosing frequency was reduced according to the summary of product characteristics to 284 mg every 2 weeks for thrombocytopenia (<100,000 per cubic millimeter) and platelet count returned to baseline or near-baseline levels after dose reduction. The mean time from the beginning of the therapy to dose reduction was 343.125 ± 208.13 days (range, 34–627).

In seven cases (30.4%), this treatment schedule was maintained due to recurrent mild thrombocytopenia on weekly administration. Mean time from the beginning of the therapy to reduction to 284 mg every 2 weeks was 382.4 ± 219.6 days (range, 34–627).

Except for the two patients who suspended therapy for renal changes, we did not observe a decline in renal function, measured by estimated glomerular filtration rate and urine protein/creatinine ratio. No abnormalities in liver function tests occurred.

No cardiac-related events occurred, and we did not report any deaths in our cohort.

Efficacy end points

All secondary end point values are summarized in Table 2.

Neurologic evaluation

Considering FAP stage, two out of 23 patients (8.7%) worsened, both at M6 from Stage 2 to 3 (Figure 1).

Considering PND stage, four out of 23 patients (17.4%) worsened at M6 (two from class 3b to 4 and two from class 3a to 3b), whereas one out of 23 (4.3%) patients improved (Figure 1).

Mean NIS was 77.0 ± 37.9 at baseline and 133.2 ± 43.1 at M24. We observed an average monthly progression of 0.83 ± 1.16 on the NIS scale. We found an almost significant worsening of NIS values (p = 0.053) from baseline to M24 (Supplementary Figure S2); however, we should consider that only four patients (two FAP 2 and two FAP 3) reached this follow-up.

Mean CADT score was 14.65 ± 3.25 at baseline and 11.66 ± 0.58 at M24. We did not find a significant worsening of CADT values from baseline to M24 (Supplementary Figure S3).
Subgroups analysis

We found no significant differences in disease progression among the following subgroups: genotype, phenotype, previous treatment with tafamidis, and dose of inotersen.

Considering disease severity at baseline, FAP 1 patients progressed slower than FAP 2. NIS changes from baseline differed significantly between patients with FAP 1 stage and patients with FAP 2 stage at M6 ($p = 0.003$), M12 ($p < 0.0005$), and M18 ($p = 0.001$). Moreover, mean NIS score did not change significantly ($p = 0.984$) in FAP 1 patients along the treatment period, whereas it showed a progressive significant increase along the 24 months in FAP 2 group ($p < 0.0005$) (Figure S4). CADT was significantly higher in FAP 1 versus FAP 2 patients at baseline ($p = 0.004$), at M6 ($p = 0.044$), M12
### TABLE 1  Demographic and baseline clinical characteristics

| Patient | Mutation | Age at baseline, years | Age at diagnosis, years | Phenotype | FAP stage | PND | NIS | CADT | Norfolk-QoL | IVS, mm | Serum TTR, mg/dl |
|---------|----------|------------------------|------------------------|-----------|-----------|-----|-----|------|-------------|--------|------------------|
| 1       | T59K     | 59                     | 48                     | Mixed     | 2         | 3a  | 82.5| 8    | 113         | 25     | N/A              |
| 2       | V30M     | 62                     | 57                     | Neuropathy| 2         | 3b  | 124.5| 14   | 130         | 15     | N/A              |
| 3       | V30M     | 76                     | 72                     | Neuropathy| 2         | 3b  | 147 | 14   | 90          | N/A    | N/A              |
| 4       | V30M     | 73                     | 68                     | Mixed     | 2         | 3a  | 148 | 13   | 70          | 13     | N/A              |
| 5       | F64L     | 63                     | 60                     | Neuropathy| 1         | 2   | 19  | 19   | 20          | N/A    | 24               |
| 6       | F64L     | 71                     | 66                     | Neuropathy| 2         | 3b  | 105 | 16   | 79          | N/A    | 20               |
| 7       | V30M     | 60                     | 58                     | Mixed     | 2         | 3a  | 56  | 16   | 90          | 15     | 20               |
| 8       | F64L     | 62                     | 65                     | Neuropathy| 2         | 3b  | 93  | 11   | 92          | N/A    | 33               |
| 9       | A120S    | 78                     | 77                     | Mixed     | 1         | 2   | 40  | 15   | 68          | 18     | N/A              |
| 10      | F64L     | 82                     | 76                     | Neuropathy| 2         | 3a  | 128 | 14   | 128         | 14     | 25               |
| 11      | F64L     | 80                     | 72                     | Neuropathy| 2         | 3a  | 128 | 12   | 128         | 13     | 24               |
| 12      | F64L     | 87                     | 83                     | Neuropathy| 2         | 3a  | 88  | 14   | 88          | 14     | 23               |
| 13      | V30M     | 85                     | 84                     | Neuropathy| 2         | 3a  | 33  | 16   | 49          | N/A    | N/A              |
| 14      | V30M     | 78                     | 76                     | Mixed     | 2         | 3a  | 46.5| 16   | 58          | 16     | N/A              |
| 15      | V30M     | 69                     | 67                     | Mixed     | 2         | 3a  | 34  | 15   | 43          | 17     | N/A              |
| 16      | F64L     | 68                     | 66                     | Mixed     | 1         | 2   | 48  | 17   | 55          | 14     | 21               |
| 17      | Y78F     | 78                     | 75                     | Neuropathy| 2         | 3a  | 63  | 18   | 36          | 11     | N/A              |
| 18      | F64L     | 73                     | 71                     | Mixed     | 2         | 3a  | 79  | 13   | 65          | 16     | N/A              |
| 19      | V30M     | 67                     | 63                     | Neuropathy| 1         | 2   | 48  | 19   | 56          | 10.8   | 35               |
| 20      | F64L     | 73                     | 70                     | Neuropathy| 1         | 2   | 75  | 15   | 61          | 12.5   | 19               |
| 21      | F64L     | 71                     | 67                     | Neuropathy| 1         | 2   | 63  | 19   | 64          | 13.5   | 28               |
| 22      | F64L     | 58                     | 56                     | Neuropathy| 1         | 2   | 44  | 17   | 60          | 10.2   | 25               |
| 23      | F64L     | 71                     | 69                     | Neuropathy| 2         | 3a  | 79  | 6    | 62          | 14     | N/A              |

Abbreviations: CADT, Compound Autonomic Dysfunction Test; FAP, familial amyloid polyneuropathy; IVS, interventricular septum; N/A, not available; NIS, Neuropathy Impairment Scale; Norfolk QoL-DN, Norfolk Quality of Life–Diabetic Neuropathy questionnaire; PND, Polyneuropathy Disability score; TTR, transthyretin.

### TABLE 2  Secondary end points values (mean ± SD)

| End points          | Baseline, n = 23 | M6, n = 23 | M12, n = 21 | M18, n = 18 | M24, n = 4 |
|---------------------|------------------|------------|-------------|-------------|------------|
| NIS, 0–244 (days)   | 77.0 ± 37.9      | 85.9 ± 39.0| 91.8 ± 42.4 | 90.8 ± 39.9 | 133.2 ± 43.1 |
| CADT, 0–20 (days)   | 14.65 ± 3.25     | 14.31 ± 2.83| 13.70 ± 2.97| 13.81 ± 3.39| 11.66 ± 0.58 |
| Norfolk QoL-DN, −4 to 136 (days) | 74.1 ± 29.5 | 77.3 ± 27.9 | 77.6 ± 29.2 | 72.8 ± 25.7 | 94.5 ± 16.0 |
| Troponin, ng/ml     | 0.03 ± 0.03      | 0.02 ± 0.02| 0.01± 0.1   | 0.05 ± 0.06 | 0.3 ± 0.2 |
| NT-proBNP, pg/ml    | 596.4 ± 1073.5   | 642.0 ± 1140.6| 630.4 ± 1535.0| 7279.7 ± 1729.3| 3650.4 ± 192.7 |
| IVS, mm             | 15.4 ± 1.8       | 16.9 ± 4.3 | 16.3 ± 1.3  | 16.3 ± 1.4  | 12.55 ± 2.0  |
| eGFR                | 91.2 ± 17.5      | 95.6 ± 15.5| 90.6 ± 17.4 | 100.0 ± 26.0| 90.0 ± 13.8 |
| UPCR, mg/mmol       | 0.02 ± 0.05      | 0.02 ± 0.05| 0.3 ± 0.9   | 0.02 ± 0.08 | 0.1 ± 0.1  |
| Platelet count, ×10^12/μl | 192.2 ± 53.9 | 175.2 ± 81.1| 163.6 ± 53.6| 148.7 ± 41.7| 1470 ± 34.7 |
| BMI                 | 25.1 ± 3.4       | 24.0 ± 2.5 | 24.9 ± 3.6  | 24.2 ± 2.9  | 23.4 ± 0.6  |
| TTR, mg/dl          | 24.75 ± 5.05     | 6.07 ± 4.88| 6.17 ± 2.23 | 4.33 ± 1.53 | 5.5 ± 2.12  |

Abbreviations: BMI, body mass index; CADT, Compound Autonomic Dysfunction Test; eGFR, estimated glomerular filtration rate; IVS, interventricular septum; NIS, Neuropathy Impairment Scale; Norfolk QoL-DN, Norfolk Quality of Life–Diabetic Neuropathy; NT-proBNP, N-terminal pro–brain natriuretic peptide; TTR, transthyretin; UPCR, urine protein/creatinine ratio; M, month.

(p = 0.03), and M18 (p = 0.026) (Figure S5). However, no statistically significant deterioration in CADT values was observed both in FAP 1 and FAP 2 patients. Serum TTR concentrations did not differ in the FAP1 versus FAP2 group at baseline. Significant reduction was observed in all patients during the treatment period. Furthermore, serum TTR
concentrations did not differ at baseline and during follow-up in patients treated with the full dose of inotersen versus patients with a reduced regimen.

**Quality-of-life assessment**

Norfolk QoL-DN at baseline was 74.1 ± 29.5. The mean monthly change was 0.26 ± 0.8, with no statistical significance between time points (Figure S6).

Changes in Norfolk QoL-DN score differed significantly between FAP 1 patients and FAP 2 patients at M12 ($p = 0.042$) and M18 ($p = 0.020$). However, no statistically significant increase in Norfolk QoL-DN values was observed both in FAP 1 ($p = 0.392$) and FAP 2 patients ($p = 0.568$).

**Other variables**

Other variables including IVS thickness, BMI, troponin, and NT-proBNP did not show significant changes during inotersen treatment in the observed period.

**DISCUSSION**

ATTRv is a highly disabling multisystemic disease characterized by rapidly progressing neurological impairment that irreversibly compromises patients’ autonomy in a few years [5].

The annual deterioration rate in NIS significantly exceeds the progression observed in other peripheral neuropathies [11] and is associated with an increasing burden on quality of life [12]. A multi-center, retrospective study in ATTRv patients from different countries estimated an annual NIS change of 14.3 points from a baseline value of 32 [13]. However, progression is expected to occur more rapidly at higher disease stages [13].

In the NEURO-TTR trial, significant improvement in neurological progression and quality of life deterioration was observed in patients treated with inotersen for 15 months compared to placebo [7]. The long-term, sustained impact of this treatment on disease progression was recently confirmed in the open-label extension study [10].

To evaluate the real-world impact of inotersen, we investigated the outcome of a group of patients treated in the setting of a compassionate-use program.

Our study group differs in terms of disease severity at baseline either from the population of the NEURO-TTR trial or from other series reported in the literature. In particular, our patients showed higher NIS baseline values [14].

Despite this significant difference, during the observed follow-up, FAP stage overall remained stable in 91.3% of patients, and PND score, reflecting ability in walking, was unchanged in 78.3% and improved in 4.3% of the patients.

Neurological outcome according to NIS showed moderate worsening over the first 6 months, probably due to the time required to reach an effect [12], and then substantial stabilization was observed up to 18 months. The annual progression of NIS was lower when compared with the natural history of the disease reported in the literature (9.96 vs. 14.3 points) [13].

Quality of life according to the Norfolk QoL-DN score was preserved by inotersen treatment both in FAP 1 and FAP 2 patients. Mean annual change in Norfolk QoL-DN was only 3.2 points, which is significantly lower than the recently published threshold that defines progression [15].

Similarly, the CADT score, indicating autonomic dysfunction, remained stable along the follow-up both in FAP 1 and FAP 2 patients.

Few data are available regarding factors able to influence therapy outcome in ATTRv [12]. Subgroup analysis revealed disease stability in patients starting inotersen in FAP Stage 1 but not in those starting therapy in stage 2. These results are consistent with higher rates of progression in patients with worse baseline disease severity observed in other studies [11]. Hence, our data confirm an increased therapeutic benefit with earlier treatment.

Considering safety, inotersen proved to be safe and well tolerated over 24 months. A drug-related change in renal function was observed only in one patient, in which crescentic glomerulonephritis was shown by biopsy and was promptly reversible after inotersen discontinuation. Moreover, markers of liver and cardiac function did not change significantly during the study. Platelet count relatively decreased after 6 months but then remained stable [7].

No Grade 4 thrombocytopenia or deaths occurred in our cohort. In a few cases, a temporary or permanent dose reduction was necessary to maintain platelet count over 100,000 per microliter.

In conclusion, inotersen improves neurological progression and preserves quality of life in patients with a wide range of disease severity at treatment start, and has a good safety profile. In our cohort, worsening of neurologic function was more pronounced in patients with higher disease severity at baseline. On the contrary, health-related quality of life seemed equally preserved during the treatment course. Our data further underscore the importance of early treatment intervention with inotersen. Additional studies with a larger sample size are needed to confirm these results.

**CONFLICT OF INTEREST**

M.L. received financial grants (honoraria and speaking) from Ackea, Alnylam, and Pfizer, and travel grants from Akeca, Alnylam, Sobi, Pfizer, Kedrion, CSL Behring, and Grifols. G.A. has no potential conflicts of interest to disclose. A.D.P. received travel grants from Pfizer. L.G. acknowledges receiving speaker fees and consulting honoraria from Pfizer. M.G. acknowledges donations from Sanofi Genzyme to support research activities of her Research Unit; financial support from Pfizer, Alnylam, and Sanofi Genzyme for participation in National and International Meetings; participation in Advisory Board of Pfizer; speaker honorarium from Sanofi Genzyme. L.L. has no potential conflicts of interest to be disclosed. A.L. acknowledges...
receiving speaker fees from SOBI. F. Manganelli received personal fees for scientific events from Alfa-Sigma, Alnylam, and Akcea and has received a travel grant to attend scientific meetings from CSL Behring. A. M. acknowledges receiving speaker fees and consulting honoraria from Alnylam, Akcea, and Pfizer. R. M. acknowledges receiving speaker fees from SOBI and Pfizer. F. My has no potential conflicts of interest to be disclosed. L. O. reports speaking and consulting honoraria from Pfizer, Alnylam, Akcea, and SOBI. E. M. P. has no potential conflicts of interest to be disclosed. M. Russo acknowledges receiving speaker fees and consulting honoraria from Akcea and Alnylam and a travel grant from Pfizer. M. S. received financial grants (honoraria and speaking) from Akcea and Alnylam, and travel grants from Grifols. A. S. reports travel grants from Akcea, Alnylam, and Pfizer and consulting honoraria from Alnylam. M. T. reports travel grants from Alnylam and Sobi and a training grant sponsored by Pfizer. S. T. received personal fees for scientific events from Alnylam and travel grants to attend scientific meetings from Akcea.

**AUTHOR CONTRIBUTIONS**

Marco Luigetti: Conceptualization (lead), data curation (lead), formal analysis (lead), methodology (lead), writing–original draft (lead), writing–review & editing (lead). Giovanni Antonini: Conceptualization (equal), data curation (equal), methodology (equal), writing–review & editing (equal). Andrea Di Paolantonio: Conceptualization (equal), data curation (equal), methodology (equal), writing–review & editing (equal). Luca Gentile: Conceptualization (equal), data curation (equal), methodology (equal), writing–review & editing (equal). Marina Grandis: Conceptualization (equal), data curation (equal), methodology (equal), writing–review & editing (equal). Luca Leonardi: Conceptualization (equal), data curation (equal), methodology (equal), writing–review & editing (equal). Alessandro Lozza: Conceptualization (equal), data curation (equal), methodology (equal), writing–review & editing (equal). Fiore Manganelli: Conceptualization (equal), data curation (equal), methodology (equal), writing–review & editing (equal). Anna Mazzeo: Conceptualization (equal), data curation (equal), methodology (equal), writing–review & editing (equal). Roberta Mussinelli: Conceptualization (equal), data curation (equal), methodology (equal), writing–review & editing (equal). Filomena My: Conceptualization (equal), data curation (equal), methodology (equal), writing–review & editing (equal). Laura Obici: Conceptualization (equal), data curation (equal), methodology (equal), writing–review & editing (equal). Elena Maria Pennisi: Conceptualization (equal), data curation (equal), methodology (equal), writing–review & editing (equal). Anna Romozzi: Conceptualization (equal), data curation (equal), methodology (equal), writing–review & editing (equal). Marina Romozzi: Conceptualization (equal), data curation (equal), methodology (equal), writing–review & editing (equal). Massimo Russo: Conceptualization (equal), data curation (equal), methodology (equal), writing–review & editing (equal). Mario Sabatelli: Conceptualization (equal), data curation (equal), methodology (equal), writing–review & editing (equal). Alessandro Salvagaggio: Conceptualization (equal), data curation (equal), methodology (equal), writing–review & editing (equal). Matteo Tagliapietra: Conceptualization (equal), data curation (equal), methodology (equal), writing–review & editing (equal). Stefano Tozza: Conceptualization (equal), data curation (equal), methodology (equal), writing–review & editing (equal).

**ACKNOWLEDGEMENT**

Open Access Funding provided by Universita Cattolica del Sacro Cuore within the CRUI-CARE Agreement.

**DATA AVAILABILITY STATEMENT**

The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions.

**ORCID**

Marco Luigetti https://orcid.org/0000-0001-7539-505X
Fiore Manganelli https://orcid.org/0000-0001-9478-3744
Marina Romozzi https://orcid.org/0000-0001-6016-3141
Mario Sabatelli https://orcid.org/0000-0001-6635-4985
Alessandro Salvagaggio https://orcid.org/0000-0002-1273-7566
Matteo Tagliapietra https://orcid.org/0000-0002-3048-1453
Stefano Tozza https://orcid.org/0000-0002-9672-4577

**REFERENCES**

1. Planté-Bordeneuve V, Said G. Familial amyloid polyneuropathy. *Lancet Neurol*. 2011;10(12):1086-1097. 10.1016/S1474-4221(11)70246-0
2. Russo M, Obici L, Bartolomei I, et al. ATTRv amyloidosis Italian Registry: clinical and epidemiological data. *Amyloid*. 2020;27(4):259-265. 10.1080/13506129.2020.1794807
3. Manganelli F, Fabrizi GM, Luigetti M, et al. Hereditary transthyretin amyloidosis overview. *Neuronal Sci*. 2020. Epub Ahead of print. 10.1007/s10072-020-04889-2
4. Tozza S, Severi D, Spina E, et al. The neuropathy in hereditary transthyretin amyloidosis: a narrative review. *J Peripher Nerv Syst*. 2021;26(2):155-159. 10.1111/jns.12451
5. Luigetti M, Romano A, Di Paolantonio A, et al. Diagnosis and Treatment of Hereditary Transthyretin Amyloidosis (hATTR) polyneuropathy: current perspectives on improving patient care. *Ther Clin Risk Manag*. 2020;16:109-123. 10.2147/tcrm.s219799
6. Russo M, Gentile L, Di Stefano V, et al. Use of drugs for ATTR v amyloidosis in the real world: how therapy is changing survival in a non-endemic area. *Brain Sci*. 2021;11:545. 10.3390/brainsci11050545
7. Benson MD, Waddington-Cruz M, Berk JL, et al. Inotersen treatment for patients with hereditary transthyretin amyloidosis. *N Engl J Med*. 2018;379:22-31. 10.1056/NEJMoa1716793
8. Adams D, Gonzalez-Duarte A, Riordan WD, et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. *N Engl J Med*. 2012;79(8):785-792. 10.1111/jns.12451
9. Coelho T, Maia LF, Martins da Silva A, et al. Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial. *Neurology*. 2012;79(8):785-792. 10.1212/WNL.0b013e3182661eb1
10. Brannagan TH, Wang AK, Coelho T, et al. Early data on long-term efficacy and safety of inotersen in patients with hereditary transthyretin amyloidosis: a 2-year update from the open-label extension of the NEURO-TTR trial. *Eur J Neurol*. 2020;27(8):1374-1381. 10.1111/ene.14285
11. Lin X, Yarlas A, Vera-Llonch M, et al. Rate of neuropathic progression in hereditary transthyretin amyloidosis with polyneuropathy and other peripheral neuropathies: a systematic review and meta-analysis. *BMC Neurol*. 2021;21:70. 10.1186/s12883-021-02094-
12. Gentile L, Russo M, Luigetti M, et al. Patisiran in hATTR amyloidosis: six-month latency period before efficacy. *Brain Sci.* 2021;11:515. 10.3390/brainsci11040515

13. Adams D, Coelho T, Obici L, et al. Rapid progression of familial amyloidotic polyneuropathy: a multinational natural history study. *Neurology.* 2015;85(8):675-682. 10.1212/WNL.0000000000001870

14. Berk JL, Suhr OB, Obici L, et al. Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial. *JAMA.* 2013;310:2658-2667. 10.1001/jama.2013.283815

15. Yarlas A, Gertz MA, Dasgupta NR, et al. Burden of hereditary transthyretin amyloidosis on quality of life. *Muscle Nerve.* 2019;60:169-175. 10.1002/mus.26515

**SUPPORTING INFORMATION**
Additional supporting information may be found in the online version of the article at the publisher’s website.

**How to cite this article:** Luigetti M, Antonini G, Di Paolantonio A, et al. Real-life experience with inotersen in hereditary transthyretin amyloidosis with late-onset phenotype: Data from an early-access program in Italy. *Eur J Neurol.* 2022;29:2148–2155. doi:10.1111/ene.15325